Abstract: An electronic device includes a communication circuit, a speaker, and a processor. The processor is configured to identify a bitrate of a first audio bitstream received via the communication circuit from an external electronic device. The processor is configured to obtain, in response to the bitrate lower than a reference value, an audio signal by executing a bandwidth extension (BWE) for the first audio bitstream based on at least one coding parameter obtained from a second audio bitstream previously received via the communication circuit from the external electronic device before the first audio bitstream. The processor is configured to obtain, in response to the bitrate higher than or equal to the reference value, the audio signal for the first audio bitstream without executing the BWE. The processor is configured to output, based on the audio signal, audio via the speaker.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: The present invention relates to methods and combination therapies for enhancing the activity and function of non-B cell immune cells (such as T cells) using genetically modified B cells. These methods and combinations can be used, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like.

Abstract: An apparatus (20) for monitoring flotation performance apparatus comprises an arm (21) having a paddle (22) attached at one end. The apparatus (20) forms a sensor to monitor real-time flotation performance by measuring the drag exerted by the overflowing froth onto a cantilever beam arm. The strain exerted on the beam or arm can be directly correlated to the efficiency of the froth flotation process.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4 The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: A vehicle may include a transmission control unit (TCU) to output a control signal to the transmission; a shift lever; a shift lever electronic control unit (ECU) to transmit a first signal and a second signal, to the TCU; a main communication unit to perform communication between the TCU and the shift lever ECU; a backup communication unit to perform communication between the TCU and the shift lever ECU; and a controller configured to: control the shift lever ECU to transmit first and second signals based on one of a plurality of matching codes having different pulse width modulation (PWM) duty ratios assigned to the respective gear positions of the transmission; determine another one of the plurality of matching codes when the operation commands indicated by each of the first signal and the second signal received by the TCU are different; and control the shift lever ECU based on the determined matching code.

Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: A vehicle may include a transmission control unit (TCU) to output a control signal to the transmission; a shift lever; a shift lever electronic control unit (ECU) to transmit a first signal and a second signal, to the TCU; a main communication unit to perform communication between the TCU and the shift lever ECU; a backup communication unit to perform communication between the TCU and the shift lever ECU; and a controller configured to: control the shift lever ECU to transmit first and second signals based on one of a plurality of matching codes having different pulse width modulation (PWM) duty ratios assigned to the respective gear positions of the transmission; determine another one of the plurality of matching codes when the operation commands indicated by each of the first signal and the second signal received by the TCU are different; and control the shift lever ECU based on the determined matching code.

Abstract: A transmission parking system is provided. The system includes a parking gear and a parking rod that is connected with the parking gear. Additionally, a parking lever has a first end that is connected with the parking rod and the parking lever is installed rotatably around a control shaft. A detent return spring is wound around an exterior circumference of the control shaft, supports the parking lever, and provides elastic force to rotate the parking lever and return to an original position. A control lever is installed rotatably around the control shaft and is installed at an exterior side of the parking lever to allow user operation. A neutral state maintaining lock and release device is connected with the control lever and is changed to a neutral state lock or a neutral state release based on operation of the control lever.

Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: The present invention is directed toward neutralizing monoclonal antibodies to Vascular Endothelial Growth Factor (VEGF) and angiopoietin 2 (Ang-2), pharmaceutical compositions comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: The present invention relates to an operation method of a washing machine for controlling the rotation of a pulsator to enhance cleaning performance, there is provided a method of operating a washing machine having a pulsator rotatably provided in a tub, and the method may include a first cleaning mode having a first process of rotating the pulsator in one direction at a first angle and then rotating it in the other direction at a second angle around the rotation shaft; and a second process of rotating the pulsator in the one direction at a third angle and then rotating it in the other direction at a fourth angle around the rotation shaft, wherein the first angle is greater than the third angle, and the second angle is greater than the fourth angle, and the second angle is greater than the third angle.